Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria

Nature Reviews Microbiology

Volumn 6, Issue 5, 2008, Pages 349-362

  Wells, Jerry M ^a   Mercenier, Annick ^b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DNA VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; M PROTEIN; PROTEIN E7; PROTEIN LCRV; RECOMBINANT INTERLEUKIN 10; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TETANUS TOXIN; TREFOIL PEPTIDE; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGENICITY; BACTERIAL CELL WALL; BRUCELLA ABORTUS; CLINICAL TRIAL; COLITIS; CYTOKINE RELEASE; DENTAL CARIES; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; ENTERITIS; ENTEROTOXIGENIC ESCHERICHIA COLI; ERYSIPELOTHRIX RHUSIOPATHIAE; HELICOBACTER PYLORI; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; INFECTIOUS BURSAL DISEASE VIRUS; LACTIC ACID BACTERIUM; LACTOBACILLUS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS ZEAE; LACTOCOCCUS LACTIS; NONHUMAN; PLASMODIUM YOELII; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; SARS CORONAVIRUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PYOGENES; TETANUS; VIRUS ENTRY;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, MUCOSAL; LACTIC ACID; LACTOBACILLUS; MICE; MUCOUS MEMBRANE; RECOMBINANT PROTEINS; STREPTOCOCCACEAE; VACCINES, DNA;

BACTERIA (MICROORGANISMS); LACTOCOCCUS;

EID: 42349105761     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro1840     Document Type: Review

References (103)

1. Hayashi, H., Takahashi, R., Nishi, T., Sakamoto, M. & Benno, Y. Molecular analysis of jejunal, ileal, caecal and recto-sigmoidal human colonic microbiota using 16S rRNA gene libraries and terminal restriction fragment length polymorphism. J. Med. Microbiol. 54 1093-1101 (2005).
2. Lavelle, E. C. & O'Hagan, D. T. Delivery systems and adjuvants for oral vaccines. Expert Opin. Drug Deliv. 3, 747-762 (2006).
3. Malik, D. K., Baboota, S., Ahuja, A., Hasan, S. & Ali, J. Recent advances in protein and peptide drug delivery systems. Curr. Drug Deliv. 4, 141-151 (2007).
4. Wernerus, H. & Stahl, S. Biotechnological applications for surface-engineered bacteria. Biotechnol. Appl. Biochem. 40, 209-228 (2004).
5. Uyen, N. Q., Hong, H. A. & Cutting, S. M. Enhanced immunisation and expression strategies using bacterial spores as heat-stable vaccine delivery vehicles. Vaccine 25, 356-365 (2007).
6. Pozzi, G., Oggioni, M. R. & Medaglini, D. in Gram-positive bacteria as vaccine vehicles for mucosal immunisation (eds Pozzi, G. & Wells, J. M.) 35-60 (Landes, Austin, 1997).
7. Foligne, B. et al. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein Gastroenterology 133, 862-874 (2007).
8. Frossard, C. P., Steidler, L. & Eigenmann, P. A. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J. Allergy Clin. Immunol. 119, 952-959 (2007).
9. Hanniffy, S. B., Carter, A. T., Hitchin, E. & Wells, J. M. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J. Infect. Dis. 195, 185-193 (2007).
10. Cortes-Perez, N. G. et al. Intranasal coadministration of live lactococci producing interleukin-12 and a major cow's milk allergen inhibits allergic reaction in mice. Clin. Vaccine Immunol. 14 226-233 (2007).
11. Braat, H. et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4, 754-759 (2006).
12. Neutra, M. R. & Kozlowski, P. A. Mucosal vaccines: The promise and the challenge. Nature Rev. Immunol. 6, 148-158 (2006).
13. Roland, K. L., Tinge, S. A., Killeen, K. P. & Kochi, S. K. Recent advances in the development of live, attenuated bacterial vectors. Curr. Opin. Mol. Ther. 7, 62-72 (2005).
14. Daudel, D., Weidinger, C. & Spreng, S. Use of attenuated bacteria as delivery vectors for DNA vaccines. Expert Rev. Vaccines 6, 97-110 (2007).
15. Tacket, C. O. & Levine, M. M. CVD 908, CVD 908-htrA, and CVD-909 live oral typhoid vaccines: A logical progression. Clin. Infect. Dis. 45, S20-S23 (2007).
16. Mannam, P., Jones, K. F. & Geller, B. L. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun. 72, 3444-3450 (2004).
17. Gilbert, C., Robinson, K., Le Page, R. W. & Wells, J. M. Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in Lactococcus lactis. Infect. Immun. 68, 3251-3260 (2000).
18. Mowat, A. M., Millington, O. R. & Chirdo, F. G. Anatomical and cellular basis of immunity and tolerance in the intestine. J. Pediatr. Gastroenterol. Nutr. 39, S723-S724 (2004).
19. Rescigno, M. et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nature Immunol. 2, 361-367 (2001).
20. Chieppa, M., Rescigno, M., Huang, A. Y. & Germain, R. N. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement. J. Exp. Med. 203, 2841-2852 (2006).
21. Macpherson, A. J. & Uhr, T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 303, 1662-1665 (2004).
22. Macpherson, A. J. IgA adaptation to the presence of commensal bacteria in the intestine. Curr Top. Microbiol. Immunol. 308, 117-136 (2006).
23. Klijn, N., Weerkamp, A. H. & de Vos, W. M. Genetic marking of Lactococcus lactis shows its survival in the human gastrointestinal tract. Appl. Environ. Microbiol. 61, 2771-2774 (1995).
24. Vesa, T., Pochart, P. & Marteau, P. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KUD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Aliment. Pharmacol. Ther. 14, 823-828 (2000).
25. Alander, M. et al. Persistence of colonization of human colonic mucosa by a probiotic strain. Lactobacillus rhamnosus GG, after oral consumption. Appl. Environ. Microbiol. 65, 351-354 (1999).
26. van der Waaij, L. A. et al. Bacterial population analysis of human colon and terminal ileum biopsies with 16S rRNA-based fluorescent probes: Commensal bacteria live in suspension and have no direct contact with epithelial cells. Inflamm. Bowel Dis. 11, 865-871 (2005).
27. Valeur, N., Engel, P., Carbajal, N., Connolly, E. & Ladefoged, K. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl. Environ. Microbiol. 70, 1176-1181 (2004).
28. Vinderola, C. G., Medici, M. & Perdigon, G. Relationship between interaction sites in the gut, hydrophobicity, mucosal immunomodulating capacities and cell wall protein profiles in indigenous and exogenous bacteria. J. Appl. Microbiol. 96, 230-243 (2004).
29. Nouaille, S. et al. Heterologous protein production and delivery systems for Lactococcus lactis. Genet. Mol. Res. 2, 102-111 (2003).
30. de Vos, W. M. Gene expression systems for lactic acid bacteria. Curr. Opin. Microbiol. 2, 289-295 (1999).
31. Mercenier, A., Muller-Alouf, H. & Grangette, C. Lactic acid bacteria as live vaccines. Curr. Issues Mol. Biol. 2, 17-25 (2000).
32. Norton, P. M. et al. Factors affecting the immunogenicity of tetanus toxin fragment C expressed in Lactococcus lactis. FEMS Immunol. Med. Microbiol. 14, 167-177 (1996).
33. Hanniffy, S. et al. Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv. Appl. Microbiol. 56, 1-64 (2004).
34. Robinson, K., Chamberlain, L M., Schofield, K. M., Wells, J. M. & Le Page, R. W. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nature Biotechnol. 15, 653-657 (1997).
35. Norton, P. M., Wells, J. M., Brown, H. W., Macpherson, A. M. & Le Page, R. W. Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C. Vaccine 15, 616-619 (1997).
36. Grangette, C. et al. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect. Immun. 69, 1547-1553 (2001).
37. Grangette, C. et al. Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence. Vaccine 20, 3304-3309 (2002).
38. Shaw, D. M. et al. Engineering the microflora to vaccinate the mucosa: Serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli. Immunology 100, 510-518 (2000).
39. Grangette, C. et al. Enhanced mucosal delivery of antigen with cell wall mutants of lactic acid bacteria. Infect. Immun. 72 2731-2737 (2004).
40. Lee, M. H., Roussel, Y., Wilks, M. & Tabaqchali, S. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine 19, 3927-3935 (2001).
41. Dieye, Y. et al. Ability of Lactococcus lactis to export viral capsid antigens: A crucial step for development of live vaccines. Appl. Environ. Microbiol. 69, 7281-7288 (2003).
42. Bermudez-Humaran, L. G. et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J. Med. Microbiol. 53, 427-433 (2004).
43. Robinson, K. et al. Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C. Infect. Immun. 72, 2753-2761 (2004).
44. Delcenserie, V. et al. Immunomodulatory effects of probiotics in the intestinal tract. Curr. Issues Mol. Biol. 10, 37-54 (2008).
45. Steidler, L. et al. Secretion of biologically active murine interleukin-2 by Lactococcus lactis subsp. lactis. Appl. Environ. Microbiol. 61, 1627-1629 (1995).
46. Steidler, L. et al. Mucosal delivery of murahe interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect. Immun. 66, 3183-3189 (1998).
47. Bermudez-Humaran, L. G. et al. A novel mutosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J. Immunol. 175, 7297-7302 (2005).
48. Cheun, H. I. et al. Protective immunity of SpaA-antigen producing Lactococcus lactis against Erysipelothrix rhusiopothiae infection. J. Appl. Microbiol. 96, 1347-1353 (2004).
49. Xin, K. O. et al. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expresring surface-bound HIV Env. Blood 102, 223-228 (2003).
50. Corthesy, B., Boris, S., Isler, P., Grangette, C. & Mercenier, A. Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori urease B subunit partially protects against challenge with Helicobacter felis. J. Infect. Dis. 192, 1441-1449 (2005).
51. Oliveira, M. L. et al. Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infect. 8 1016-1024 (2006).
52. Jechlinger, W. Optimization and delivery of plasmid DNA for vaccination. Expert Rev. Vaccines 5, 803-825 (2006).
53. Howarth, M. & Elliott, T. The processing of antigens delivered as DNA vaccines. Immunol. Rev. 199, 27-39 (2004).
54. Guimaraes, V. D. et al. Internalin-expressing Lactococcus lactis is able to invade small intestine of guinea pigs and deliver DNA into mammalian epithelial cells. Microbes Infect. 7 836-844 (2005).
55. Guimaraes, V. D. et al. Use of native lactococci as vehicles for delivery of DNA into mammalian epithelial cells. Appl. Environ. Microbiol. 72, 7091-7097 (2006).
56. Li, Y. G., Tian, F. L., Gao, F. S., Tang, X. S. & Xia, C. Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus. Vaccine 25 902-911 (2007).
57. Steidler, L. et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352-1355 (2000).
58. Steidler, L. In situ delivery of cytokines by genetically engineered Lactococcus lactis. Antonie Van Leeuwenhoek 82, 323-331 (2002).
59. Schreiber, S. et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's disease IL-10 cooperative study group. Gastroenterology 119, 1461-1472 (2000).
60. Steidler, L. et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nature Biotechnol. 21, 785-789 (2003).
61. Vandenbroucke, K. et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 127, 502-513 (2004).
62. Crameri, R. & Rhyner, C. Novel vaccines and adjuvants for allergen-specific immunotherapy. Curr. Opin. Immunol. 18, 761-768 (2006).
63. Murosaki, S. et al. Heat-killed Lactobacillus plantarum L-137 suppresses naturally fed antigen-specific IgE production by stimulation of IL-12 production in mice. J. Allergy Clin. Immunol. 102, 57-64 (1998).
64. Kruisselbrink, A., Heijne Den Bak-Glashouwer, M. J., Havenith, C. E., Thole, J. E. & Janssen, R Recombinant Lactobacillus plantarum inhibits house dust mite-specific T-cell responses. Clin. Exp. Immunol. 126, 2-8 (2001).
65. Repa, A. et al. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 22, 87-95 (2003).
66. Chatel, J. M. et al. Characterization of a Lactococcus lactis strain that secretes a major epitope of bovine beta-lactoglobulin and evaluation of its immunogenicity in mice. Appl. Environ. Microbiol. 69, 6620-6627 (2003).
67. Novak, N., Allam, J. P., Betten, H., Haberstok, J. & Bieber, T. The role of antigen presenting cells at distinct anatomic sites: They accelerate and they slow down allergies. Allergy 59, 5-14 (2004).
68. Adel-Patient, K. et al. Oral administration of recombinant Lactococcus lactis expressing bovine β-lactoglobulin partially prevents mice from sensitization. Clin. Exp. Allergy 35, 539-546 (2005).
69. Daniel, C. et al. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy 61, 812-819 (2006).
70. Daniel, C., Repa, A., Mercenier, A., Wiedermann, U. & Wells, J. The European LABDEL project and its relevance to the prevention and treatment of allergies. Allergy 62, 1237-1242 (2007).
71. Charng, Y. C., Lin, C. C. & Hsu, C. H. Inhibition of allergen-induced airway inflammation and hyperreactivity by recombinant lactic-acid bacteria. Vaccine 24, 5931-5936 (2006).
72. Huibregtse, I. L. et al. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology 133, 517-528 (2007).
73. Wu, C. et al. Immunomodulatory effects of IL-12 secreted by Lactococcus lactis on Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice. Int. Immunopharmocol. 6 610-615 (2006).
74. Boyd, M. R. et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp 120: Potential applications to microbicide development. Antimicrob. Agents Chemother. 41, 1521-1530 (1997).
75. Giomarelli, B. et al. The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. Aids 16, 1351-1356 (2002).
76. Pusch, O. et al. Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin. J. Acquir. Immune Defic. Syndr. 40, 512-520 (2005).
77. Liu, X. et al. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob. Agents Chemother. 50, 3250-3259 (2006).
78. Chang, T L. et al. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc. Natl Acad. Sci. USA 100, 11672-11677 (2003).
79. Chancey C. J. et al. Lactobacilli-expressed single-chain variable fragment (scFv) specific for intercellular adhesion molecule 1 (ICAM-1) blocks cell-associated HIV-1 transmission across a cervical epithelial monolayer. J. Immunol. 176, 5627-5636 (2006).
80. Rao, S. et al. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc. Natl Acad. Sci. USA 102, 11993-11998 (2005).
81. Pusch, O. et al. An anti-HIV microbicide engineered in commensal bacteria: Secretion of HIV-1 fusion inhibitors by lactobacilli. Aids 20, 1917-1922 (2006).
82. Falagas, M. E., Betsi, G. I. & Athanasiou, S. Probiotics for the treatment of women with bacterial vaginosis. Clin. Microbiol. Infect. 13, 657-664 (2007).
83. Chakraborty, H. et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: A probabilistic empiric model. Aids 15, 621-627 (2001).
84. Beninati, C. et al. Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nature Biotechnol. 18, 1060-1064 (2000).
85. Kruger, C. et al. In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nature Biotechnol. 20, 702-706 (2002).
86. Oliveira, M. L., Areas, A. P. & Ho, P. L. Intranasal vaccines for protection against respiratory and systemic bacterial infections. Expert Rev. Vaccines 6, 419-429 (2007).
87. Baumann, U., Gocke, K., Gewecke, B., Freihorst, J. & von Specht, B. U. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: A clinical phase I/II study. Respir. Res. 8, 57 (2007).
88. DiGiandomenico, A. et al. Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc. Natl Acad. Sci. USA 104, 4624-4629 (2007).
89. Drouault, S., Juste, C., Marteau, P., Renault, P. & Corthier, G. Oral treatment with Lactococcus lactis, expressing Staphylococcus hyicus lipase enhances lipid digestion in pigs with induced pancreatic insufficiency. Appl. Environ. Microbiol. 68, 3166-3168 (2002).
90. Han, W. et al. Improvement-of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase. Inflamm. Bowel Dis. 12, 1044-1052 (2006).
91. Salminen, S. et al. Demonstration of safety of probiotics - a review. Int. J. Food Microbiol. 44, 93-106 11 (1998)
92. Ishibashi, N. & Yamazaki, S. Probiotics and safety. Am. J. Clin. Nutr. 73, (Suppl. 2) 465-470 (2001).
93. Frey, J. Biological safety concepts of genetically modified live bacterial vaccines. Vaccine 25, 5598-5605 (2007).
94. Perez-Alvarez, L. et al. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J. Med. Virol. 78, 141-147 (2006).
95. Lee, S. F. Oral colonization and immune responses to Streptococcus gordonii: Potential use as a vector to induce antibodies against respiratory pathogens. Curr. Opin. Infect. Dis. 16. 231-235 (2003).
96. Wells, J. M., Wilson, P. W., Norton, P. M., Gasson, M. J. & Le Rage, R. W. Loctacoccus lactis: High-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol. Microbiol. 8, 1155-1162 (1993).
97. Chu, H. et al. Lactobacillus acidophilus expressing recombinant K99 adhesive fimbriae has an inhibitory effect on adhesion of enterotoxigenic Escherichia coli. Microbiol. Immunol. 49, 941-948 (2005).
98. Lee, J.S. et al. Mucosal Immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J. Virol. 80, 4079-4087 (2006).
99. Perez, C. A., Eichwald, C. Burrone, O. & Mendoza, D. Rotavirus vp7 antigen produced by Lactococcus lactis induces neutralizing antibodies in mice. J. Appl. Microbiol. 99, 1158-1164 (2005).
100. Buccato, S. et al. Use of Lactococcus loctis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease. J. Infect, Dis. 194 331-340 (2006).
101. Pontes, D. S. et al. Induction of partial protection in mice after oral administration of Lactococcus lactis producing Brucella abortus L7/L12 antigen. J. Drug Target. 11, 489-493 (2003).
102. Po, H. et al. Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice. Int. J. Cancer 119, 1702-1709 (2006).
103. 19- World J. Gastroenterol. 11, 6975-6980 (2005).